糖心视频

COVID-19 Health, Wellness & Biotech

CRISPR Biotech Company Mammoth Biosciences Gains Unicorn Status

illustration of biotech lab equipment

San Francisco-based has closed on a $150 million Series D led by , fast on the heels of its $45 million Series C raised in November 2020.

Subscribe to the Crunchbase Daily

With its most recent funding, the company is now valued at $1 billion and joins the .

Trevor Martin, CEO and co-founder of Mammoth Biosciences

We spoke with , CEO and co-founder of Mammoth Biosciences on its CRISPR applications. CRISPR is a technology that permits gene editing by in a cell.

鈥淲e’ve been able to develop proteins to have huge advantages for different therapeutic applications, in particular, in vivo applications, so that you can build permanent genetic cures, rather than just treatments,鈥 said Martin.

In particular, the company is pioneering 鈥渦ltra small CRISPR systems鈥 to build more efficient in vivo therapies.

In vivo therapies are performed inside the body of a living organism.

The company also operates in the new field of CRISPR-based diagnostics. It has built a foundation, in the four years since its founding, of 鈥渢he largest toolbox of CRISPR proteins on earth,鈥 said Martin. Its North Star for diagnostics is 鈥渄emocratizing access to high quality molecular information.鈥

Amongst its co-founders, the company counts , one of the inventors of CRISPR. Doudna is also the chair of Mammoth’s scientific advisory board.聽

Prior to the pandemic, Mammoth had been interested in leveraging its diagnostics platform for , and 聽 to use its DETECTR聽platform for nucleic acid testing. These tests do not require bulky lab equipment and can produce rapid results at the testing location.聽聽

鈥淥ur diagnostic programs have been accelerated by our work in COVID, but maybe less publicly and just as importantly we’ve really shown that these ultra small systems are incredibly powerful for therapeutic applications. That’s extremely unique and a very exciting area that we’ve unlocked on that side,鈥 said Martin on raising its most recent funding round.

Participants in the latest funding include Foresite Capital, , , 1, and . The company is also beefing up its management team and announced , a biotech veteran, as its general counsel.聽聽

Illustration:


  1. Mayfield Fund is an investor in Crunchbase. It has no say in our editorial process. For more, head here.

Stay up to date with recent funding rounds, acquisitions, and more with the Crunchbase Daily.

67.1K Followers

CTA

Discover and act on private market opportunities with predictive company intelligence.

Copy link